logo
Trump's Labor Department proposes more than 60 rule changes in a push to deregulate workplaces

Trump's Labor Department proposes more than 60 rule changes in a push to deregulate workplaces

NEW YORK (AP) — The U.S. Department of Labor is aiming to rewrite or repeal more than 60 'obsolete' workplace regulations, ranging from minimum wage requirements for home health care workers and people with disabilities to standards governing exposure to harmful substances.
If approved, the wide-ranging changes unveiled this month also would affect working conditions at constructions sites and in mines, and limit the government's ability to penalize employers if workers are injured or killed while engaging in inherently risky activities such as movie stunts or animal training.
The Labor Department says the goal is to reduce costly, burdensome rules imposed under previous administrations, and to deliver on President Donald Trump's commitment to restore American prosperity through deregulation.
'The Department of Labor is proud to lead the way by eliminating unnecessary regulations that stifle growth and limit opportunity,' Secretary of Labor Lori Chavez-DeRemer said in a statement, which boasted the 'most ambitious proposal to slash red tape of any department across the federal government.'
Critics say the proposals would put workers at greater risk of harm, with women and members of minority groups bearing a disproportionate impact.
'People are at very great risk of dying on the job already,' Rebecca Reindel, the AFL-CIO union's occupational safety and health director, said. 'This is something that is only going to make the problem worse.'
The proposed changes have several stages to get through before they can take effect, including a public comment period for each one.
Here's a look at some of the rollbacks under consideration:
No minimum wage for home health care workers
Home health care workers help elderly or medically fragile people by preparing meals, administering medications, assisting with toilet use, accompanying clients to doctor appointments and performing other tasks. Under one of the Labor Department's proposals, an estimated 3.7 million workers employed by home care agencies could be paid below the federal minimum wage — currently $7.25 per hour — and made ineligible for overtime pay if they aren't covered by corresponding state laws.
The proposed rule would reverse changes made in 2013 under former President Barack Obama and revert to a regulatory framework from 1975. The Labor Department says that by lowering labor and compliance costs, its revisions might expand the home care market and help keep frail individuals in their homes for longer.
Judy Conti, director of government affairs at the National Employment Law Project, said her organization plans to work hard to defeat the proposal. Home health workers are subject to injuries from lifting clients, and 'before those (2013) regulations, it was very common for home care workers to work 50, 60 and maybe even more hours a week, without getting any overtime pay,' Conti said.
Others endorse the proposal, including the Independent Women's Forum, a conservative nonprofit based in Virginia. Women often bear the brunt of family caregiving responsibilities, so making home care more affordable would help women balance work and personal responsibilities, the group's president, Carrie Lukas, said.
'We're pleased to see the Trump administration moving forward on rolling back some of what we saw as counterproductive micromanaging of relationships that were making it hard for people to get the care they need,' Lukas said.
Samantha Sanders, director of government affairs and advocacy at the nonprofit Economic Policy Institute, said the repeal would not constitute a win for women.
'Saying we actually don't think they need those protections would be pretty devastating to a workforce that performs really essential work and is very heavily dominated by women, and women of color in particular,' Sanders said.
Protections for migrant farm workers
Last year, the Labor Department finalized rules that provided protections to migrant farmworkers who held H-2A visas. The current administration says most of those rules placed unnecessary and costly requirements on employers.
Under the new proposal, the Labor Department would rescind a requirement for most employer-provided transportation to have seat belts for those agriculture workers.
The department is also proposing to reverse a 2024 rule that protected migrant farmworkers from retaliation for activities such as filing a complaint, testifying or participating in an investigation, hearing or proceeding.
'There's a long history of retaliation against workers who speak up against abuses in farm work. And with H-2A it's even worse because the employer can just not renew your visa,' said Lori Johnson, senior attorney at Farmworker Justice.
Michael Marsh, president and CEO of the National Council of Agricultural Employers, applauded the deregulation efforts, saying farmers were hit with thousands of pages of regulations pertaining to migrant farmworkers in recent years.
'Can you imagine a farmer and his or her spouse trying to navigate 3,000 new pages of regulation in 18 months and then be liable for every one of them?' he asked.
Adequate lighting for construction spaces
The Occupational Safety and Health Administration, part of the Labor Department, wants to rescind a requirement for employers to provide adequate lighting at construction sites, saying the regulation doesn't substantially reduce a significant risk.
OSHA said if employers fail to correct lighting deficiencies at construction worksites, the agency can issue citations under its 'general duty clause.' The clause requires employers to provide a place of employment free from recognized hazards which are likely to cause death or serious physical harm.
Worker advocates think getting rid of a specific construction site requirement is a bad idea. 'There have been many fatalities where workers fall through a hole in the floor, where there's not adequate lighting,' Reindel said. 'It's a very obvious thing that employers should address, but unfortunately it's one of those things where we need a standard, and it's violated all the time.'
Mine safety
Several proposals could impact safety procedures for mines. For example, employers have to submit plans for ventilation and preventing roof collapses in coal mines for review by the Labor Department's Mine Safety and Health Administration. Currently, MSHA district managers can require mine operators to take additional steps to improve those plans.
The Labor Department wants to end that authority, saying the current regulations give the district manager the ability to draft and create laws without soliciting comments or action by Congress.
Similarly, the department is proposing to strip district managers of their ability to require changes to mine health and safety training programs.
Limiting OSHA's reach
The general duty clause allows OSHA to punish employers for unsafe working conditions when there's no specific standard in place to cover a situation.
An OSHA proposal would exclude the agency from applying the clause to prohibit, restrict or penalize employers for 'inherently risky professional activities that are intrinsic to professional, athletic, or entertainment occupations.'
A preliminary analysis identified athletes, actors, dancers, musicians, other entertainers and journalists as among the types of workers the limitation would apply to.
'It is simply not plausible to assert that Congress, when passing the Occupational Safety and Health Act, silently intended to authorize the Department of Labor to eliminate familiar sports and entertainment practices, such as punt returns in the NFL, speeding in NASCAR, or the whale show at SeaWorld,' the proposed rule reads.
Debbie Berkowitz, who served as OSHA chief of staff during the Obama administration, said she thinks limiting the agency's enforcement authority would be a mistake.
'Once you start taking that threat away, you could return to where they'll throw safety to the wind, because there are other production pressures they have,' Berkowitz said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late?
Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late?

Yahoo

time14 minutes ago

  • Yahoo

Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late?

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 Value Index, which returned 3.79% for the same period. The fund's top 5 holdings are also listed in the letter, showing the firm's main investment positions heading into 2025. One of the companies mentioned in the letter is UnitedHealth Group Inc. (NYSE:UNH). UnitedHealth Group Inc. (NYSE:UNH) operates as a health care company in the United States and internationally. Over the past month, UnitedHealth Group Inc. (NYSE:UNH) fell by -15.12%, and it went down to -54.69% over the last 12 months. On July 29, 2025, UnitedHealth Group Inc. (NYSE:UNH) shares closed at $261.07, with a market value of $236.83 billion. Here is what they have to say about UnitedHealth Group Inc. (NYSE:UNH) in their investor letter: "UnitedHealth Group declined as the company battled with the fallout of missing earnings forecasts and the abrupt resignation of Chief Executive Andrew Witty. We are optimistic that execution will significantly improve with the return of former CEO Stephen Hemsley." Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late? UnitedHealth Group Inc. (NYSE:UNH) ranks 18th in our list of the 30 most popular stocks among hedge funds. According to our data, 139 hedge fund portfolios held positions in UnitedHealth Group Inc. (NYSE:UNH) at the end of the first quarter of 2025, down from 150 in the previous quarter. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. UnitedHealth Group Inc. (NYSE:UNH) ranks 18th in our list of the 30 most popular stocks among hedge funds. According to our data, 139 hedge fund portfolios held positions in UnitedHealth Group Inc. (NYSE:UNH) at the end of the first quarter of 2025, down from 150 in the previous quarter. While we acknowledge the risk and potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UNH and that has 10,000% upside potential, check out our report about this cheapest AI stock. In another article, we covered UnitedHealth Group Inc. (NYSE:UNH) and Barclays analyst Andrew Mok's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Yahoo

time14 minutes ago

  • Yahoo

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA. Date: Wednesday, August 13, 2025Time: 2:00-2:25PM ESTWebcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on A replay of the webcast will be archived for up to 90 days following the session date. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). In May 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company's platforms; and expectations regarding the potential benefits conferred by Regenerative Medicine Advanced Therapy Designation, Fast Track Designation, Orphan Drug Designation or Orphan Designation. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor ContactTheodore JenkinsVice President, Investor Relations and Business DevelopmentCandel Therapeutics, Media ContactBen ShannonVice PresidentICR Healthcare CandelPR@ produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información

Beyond The Merger: A Data-Driven Playbook For Healthcare Integration
Beyond The Merger: A Data-Driven Playbook For Healthcare Integration

Forbes

time17 minutes ago

  • Forbes

Beyond The Merger: A Data-Driven Playbook For Healthcare Integration

Dave Albano, President of has more than 35 years of technology industry leadership experience. Mergers and acquisitions (M&As) are accelerating across healthcare—combining hospitals, physician groups, payers and digital health platforms in pursuit of scale, integrated care and better financial performance. However, the value of these deals often hinges on something far less glamorous: how quickly and securely the combined organization can merge and unlock value from inherited data. Meanwhile, M&A is a stress test across three critical domains: • Operational systems—from EHRs to scheduling tools—must be integrated to avoid disruption to patient care and clinician workflows. • Financial systems must be reconciled to ensure billing, revenue cycle management and forecasting remain accurate across legacy platforms. • Compliance requirements must be maintained across both entities, even as policies, access controls and reporting obligations shift under new ownership. In short, M&As create a perfect storm of fragmented systems, increased regulatory scrutiny and pressure to deliver value fast. The Post-M&A Data Landscape With each merger, multiple EHRs, claims systems, analytics tools and governance frameworks converge. This introduces a new layer of complexity, as most systems were built in isolation and weren't designed to talk to each other. Even beyond infrastructure, the business logic within these systems often diverges. Definitions for metrics like "encounter," "denial" or "readmission" can vary significantly. Getting to a shared view of operational performance, financial health and patient outcomes takes more than mapping data fields; it requires reconciling business processes and compliance assumptions. Timelines for these efforts are frequently underestimated. Data unification delays can stretch 12 to 18 months post-close, stalling the very efficiencies the deal was meant to unlock. To avoid these slowdowns, many leading organizations are investing early in centralized data repositories that unify fragmented pipelines, normalize definitions and support near real-time reporting across all departments. Non-Negotiables: Security And Compliance Healthcare data is highly regulated, and M&A activity intensifies those obligations. New data sharing workflows, unfamiliar vendors and transitional access permissions all increase exposure to security and privacy risks. Regulatory requirements such as HIPAA, HITECH and FTC breach notification rules remain in full effect during integration. In addition, state-level privacy laws like the California Consumer Privacy Act (CCPA) or others may apply depending on the entities involved. One common blind spot is user access. Orphaned accounts, inconsistent MFA enforcement and misaligned role definitions can allow unauthorized access to systems or data. Without a rapid, coordinated review of identity and access controls, the merged organization may be out of compliance from day one. The goal isn't just passing an audit. It's building trust with regulators, partners and patients. Organizations that succeed in this phase standardize identity governance across systems, implement centralized audit logging and surface compliance metrics in real time—turning regulatory risk into a managed, measurable process. Operational Challenges Beyond compliance, M&A introduces significant operational pressure. Redundant data pipelines, mismatched formats and unclear lineage slow everything from scheduling and claims to reporting and analytics. Many mid-market organizations rely on a patchwork of point tools or manual workflows—systems that may have worked before the merger but don't scale well under the increased load. The result is duplicated effort, more room for error and difficulty reconciling key performance indicators across the new entity. Even minor inconsistencies in data flows can impact clinical decisions, delay reimbursements or skew forecasts. Business continuity depends on information being not only available but also accurate, consistent and timely. Talent, Turnover And The Mid-Market Gap Post-merger environments often experience talent attrition and shifting roles. Institutional knowledge may walk out the door, and already lean teams are asked to do more with less—sometimes using unfamiliar systems. For mid-sized healthcare organizations, this is a major constraint. Teams can't rely on deep benches of engineers or expensive consultants to carry the weight of integration. That's why scalable, user-friendly platforms—designed around real workflows and supported by continuous feedback loops—are critical to long-term success. When systems are intuitive, front-line adoption increases, training costs fall and institutional knowledge is more easily retained. Bringing Order To The Chaos While no two mergers are alike, successful integrations share a common foundation—a focus on secure, scalable and efficient data unification. Prioritizing the following steps can help organizations avoid disruption, reduce risk and accelerate time to value: 1. Map what you have. Lay the foundation for trust and interoperability. Start by cataloging systems, data sources and access points across both organizations. Identify sensitive data, understand where it resides and how it's currently used. 2. Unify access and oversight. Establish governance that spans the new enterprise. Align access controls using role-based permissions. Ensure governance policies span all environments, including cloud and on-premises systems. 3. Enable seamless data flow. Support clinical accuracy and operational speed. Facilitate timely data exchange between systems to avoid discrepancies or duplication. Ensure updates to records are reflected everywhere they're needed. 4. Monitor critical workflows. Stay ahead of potential disruptions. Implement visibility into key workflows like ETL pipelines and reporting jobs. Early detection of delays or failures prevents downstream disruptions. 5. Automate where you can. Reduce manual effort and strengthen compliance. Use automation to support consistency—especially around access provisioning, audit logging and enforcement of compliance policies. This helps mitigate staffing gaps and reduces manual overhead. M&As can be transformative—but only if the underlying data and systems are securely and intelligently integrated. For healthcare organizations, this isn't just about operational alignment; it's about ensuring continuity of care, protecting patient trust and meeting the regulatory demands that govern the industry. Post-M&A integration must go beyond technical compatibility. It requires creating a unified view of operational and clinical data, delivering real-time insights to front-line care teams and embedding a culture of data-driven decision making from the C-suite to the clinic floor. That means automating manual processes, eliminating data silos and building scalable systems that support care delivery as much as they support compliance and financial stewardship. When done right, integration becomes more than a back-office function—it becomes a driver of better outcomes, faster decisions and more resilient care networks. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store